Top wikifolio Medizin-Revolution fits4u +8.2 % since Beginning +6.5 % 1 Year TOP WIKIFOLIO TRADE Buy 2024-09-26 at 03:26 pm ANNOVIS BIO INC. DL-,0001 US03615A1088 Price (EUR) 7.310 40.7% Last Activity Medizin-Revolution One U.S. biotech company nearing a significant milestone in Alzheimer's treatment is Annovis Bio. The company is developing a drug called Buntanetap (formerly Posiphen), which targets several neurotoxic proteins involved in Alzheimer's and other neurodegenerative diseases. It aims to improve brain function by enhancing synaptic transmission and reducing inflammation. Results from Phase 2/3 clinical trials are expected soon, potentially marking a breakthrough in treating Alzheimer's( https://www.biomedwire.com/annovis-bio-inc-nyse-anvs-ceo-discusses-findings-of-buntanetap-phase-2-3-alzheimers-study-on-the-bell2bell-podcast/ ).
Medizin-Revolution One U.S. biotech company nearing a significant milestone in Alzheimer's treatment is Annovis Bio. The company is developing a drug called Buntanetap (formerly Posiphen), which targets several neurotoxic proteins involved in Alzheimer's and other neurodegenerative diseases. It aims to improve brain function by enhancing synaptic transmission and reducing inflammation. Results from Phase 2/3 clinical trials are expected soon, potentially marking a breakthrough in treating Alzheimer's( https://www.biomedwire.com/annovis-bio-inc-nyse-anvs-ceo-discusses-findings-of-buntanetap-phase-2-3-alzheimers-study-on-the-bell2bell-podcast/ ).
